Feed / BCRX

BioCryst Pharmaceuticals, Inc.

BCRX

Healthcare · 9.56 -1.1% today

Partial group confirmationMarket checked 21 Aug, 15:55 GMT-4

Jodie situation report

BioCryst Pharmaceuticals, Inc.'s move is being confirmed by its market group.

BCRX accounts for 6.0% of the group's measured movement across 3.9 effective names. raw member direction is mixed; 3 of 5 session-normalized paths align to the downside. Capital-flow agreement is 29%, so confirmation is not yet clean. No verified headline preceded the measured group move.

MOVE ANATOMY

Is this move genuinely shared?

Session-normalized 5m paths
Role in the moveAligned contributor#5 of 5 by movement share
Group movement share6.0%Absolute path energy—not portfolio weight
Relative path-0.52%aligned
Effective breadth3.9 / 5balanced
Relative alignment3/5downside path · 2 counter-moving
Capital-flow agreement29%not yet clean
SEQUENCE READ

IDYA, CELC, RVMD moved materially before BCRX. BCRX crossed its material path threshold at 14:00 ET, 270 minutes after the first measured mover. ABVX followed.

What changed
  • Revenue increased 33.6% versus the comparable filing period.
EVIDENCE COVERAGE

5 of 5 members in Clinical Biotechnology are active. 0 of 6 disclosed connections are confirming.

What would change this read
  • At least 4 of 5 members remain active in the next snapshot.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as ABCL begins moving with the group.

Invalidation: The live read weakens if participation falls to 1 of 5 members or fewer.

Watch this read

Who this business touches

The relationships behind BCRX

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

CLSDQFiling-linked namepartnerFeb 26, 2026

Avoralstat We are developing our investigational plasma kallikrein inhibitor, avoralstat, with Clearside Biomedical, Inc.’s SCS Microinjector ® to deliver avoralstat to the back of the eye through the suprachoroidal space to treat patients with diabetic macul…

SGIOFFiling-linked namepartnerFeb 26, 2026

In January 2010, our partner, Shionogi, received the first approval for peramivir injection and launched it in Japan under the commercial name RAPIACTA.

NBRGFiling-linked namepartnerFeb 26, 2026

In 2021, we entered into supply and distribution agreements with Neopharm Ltd.

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 7 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

BCRX is currently a Early Follower in the organic co-movement group Clinical Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.